Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Stoop, Marcel P ^a   Singh, Vaibhav ^a   Dekker, Lennard J ^a   Titulaer, Mark K ^a   Stingl, Christoph ^a   Burgers, Peter C ^a   Sillevis Smitt, Peter A E ^a   Hintzen, Rogier Q ^a   Luider, Theo M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; JAGGED1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; VITAMIN D BINDING PROTEIN; ZINC FINGER PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEOMICS; WESTERN BLOTTING; AMINO ACID SEQUENCE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CHEMISTRY; DISEASE COURSE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; RECURRENT DISEASE;

ADULT; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CEREBROSPINAL FLUID PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; PEPTIDE FRAGMENTS; PROTEOMICS; RECURRENCE;

EID: 77957893287     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012442     Document Type: Article

References (40)

1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502-1517.
2. Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6: 903-912.
3. Hoppenbrouwers IA, Cortes LM, Aulchenko YS, Sintnicolaas K, Njajou O, et al. (2007) Familial clustering of multiple sclerosis in a Dutch genetic isolate. Mult Scler 13: 17-24.
4. Richards RG, Sampson FC, Beard SM, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6: 1-73.
5. Lassmann H (2007) New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 7: 239-244.
6. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, et al. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451: 1076-1081.
7. Liu S, Bai S, Qin Z, Yang Y, Cui Y, et al. (2009) Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 13: 1586-1603.
8. Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, et al. (2009) CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 452: 214-217.
9. Lehmensiek V, Sussmuth SD, Tauscher G, Brettschneider J, Felk S, et al. (2007) Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 13: 840-849.
10. Stoop MP, Dekker LJ, Titulaer MK, Burgers PC, Sillevis Smitt PA, et al. (2008) Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 8: 1576-1585.
11. Chiasserini D, Di Filippo M, Candeliere A, Susta F, Orvietani PL, et al. (2008) CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. Eur J Neurol 15: 998-1001.
12. Stoop MP, Dekker LJ, Titulaer MK, Lamers RJ, Burgers PC, et al. (2009) Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 8: 1404-1414.
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
14. Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Tellez N, et al. (2009) Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler 15: 1459-1465.
15. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, et al. (2005) Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics 4: 2010-2021.
16. You JS, Gelfanova V, Knierman MD, Witzmann FA, Wang M, et al. (2005) The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 5: 290-296.
17. Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, et al. (2001) Increased intrathecal production of apolipoprotein D in multiple sclerosis. J Neuroimmunol 119: 327-332.
18. Di Pauli F, Gredler V, Kuenz B, Lutterotti A, Ehling R, et al. (2010) Features of intrathecal immunoglobulins in patients with multiple sclerosis. J Neurol Sci 288: 147-150.
19. Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W (2008) Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 255: 1508-1514.
20. Gaiano N, Fishell G (2002) The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci 25: 471-490.
21. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, et al. (2002) Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8: 1115-1121.
22. The Games Collaborative G, Ban M, Booth D, Heard R, Stewart G, et al. (2006) Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. J Neuroimmunol 179: 108-116.
23. Kijima M, Iwata A, Maekawa Y, Uehara H, Izumi K, et al. (2009) Jagged1 suppresses collagen-induced arthritis by indirectly providing a negative signal in CD8+ T cells. J Immunol 182: 3566-3572.
24. Stidworthy MF, Genoud S, Li WW, Leone DP, Mantei N, et al. (2004) Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 127: 1928-1941.
25. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK (2007) Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol 113: 195-203.
26. Palacios R, Goni J, Martinez-Forero I, Iranzo J, Sepulcre J, et al. (2007) A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS ONE 2: e1222.
27. Cantorna MT (2000) Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 223: 230-233.
28. Lips P (2004) Which circulating level of 25-hydroxyvitamin D is appropriate? J Steroid Biochem Mol Biol 89-90: 611-614.
29. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, et al. (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68: 261-269.
30. Adorini L (2001) Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis. J Chemother 13: 219-234.
31. Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229: 1136-1142.
32. Raghuwanshi A, Joshi SS, Christakos S (2008) Vitamin D and multiple sclerosis. J Cell Biochem 105: 338-343.
33. Bikle DD, Siiteri PK, Ryzen E, Haddad JG (1985) Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 61: 969-975.
34. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, et al. (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63: 954-959.
35. Qin Z, Qin Y, Liu S (2009) Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 29: 203-210.
36. Shah AB, DiMartino SJ, Trujillo G, Kew RR (2006) Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1,25(OH)2 vitamin D3. Mol Immunol 43: 1109-1115.
37. Gomme PT, Bertolini J (2004) Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 22: 340-345.
38. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65: 239-248.
39. Do Carmo S, Jacomy H, Talbot PJ, Rassart E (2008) Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice. J Neurosci 28: 10330-10338.
40. Ouardouz M, Coderre E, Basak A, Chen A, Zamponi GW, et al. (2009) Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Ann Neurol 65: 151-159.